Skip to main content
PCSA logo

Processa Pharmaceuticals, Inc.

PCSANASDAQHealthcareBiotechnology

$1.68Today:- (-)1Y −81.34%

As of Oct 15, 2026 close

Market cap
$4.62M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.04$11.00
Volume (live)
-
Avg. volume (3M)
137.93K

Processa Pharmaceuticals (PCSA) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Processa Pharmaceuticals used $11.39M of cash in operating activities and spent $5.00 on capital expenditures. That left free cash flow of −$11.39M. It repurchased $10.40K of its own shares.

Processa Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Processa Pharmaceuticals, Inc. (PCSA) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-13.56-11.85-11.12-27.42-11.43-14.41-3.36-3.77-1.86
Depreciation & Amortization0.070.000.000.790.790.800.800.630.00
Deferred Income Tax0.000.000.000.00-0.53-1.00-0.60-0.900.00
Stock Based Compensation0.860.631.068.833.412.730.510.070.00
Change in Working Capital1.54-0.110.610.54-1.18-0.14-0.180.190.16
Change in Accounts Receivable0.000.000.000.070.01-0.080.000.000.00
Change in Inventory0.000.000.000.00-0.010.080.000.000.00
Change in Accounts Payable0.180.57-0.020.11-0.100.25-0.220.240.00
Change in Other Working Capital0.77-0.681.390.36-1.08-0.310.04-0.050.15
Other Operating Activities-0.300.091.397.660.22-0.920.080.070.04
Net Cash from Operating Activities-11.39-11.25-8.06-9.61-8.72-3.14-2.75-3.71-1.65
Investing Activities
Capital Expenditures0.000.000.000.000.000.000.00-0.02-0.02
Acquisitions0.000.000.000.000.000.000.000.000.01
Purchases of Investments-0.850.000.000.000.000.000.000.000.00
Other Investing Activities0.000.000.000.000.000.000.000.001.02
Net Cash from Investing Activities-0.850.000.000.000.000.000.00-0.021.00
Financing Activities
Debt Repayment-0.01-0.010.000.000.000.860.810.002.58
Common Stock Issued16.607.766.320.0010.0517.100.002.870.00
Common Stock Repurchased0.01-0.020.00-0.39-0.06-0.100.000.000.00
Other Financing Activities-0.01-0.01-0.050.00-0.190.000.90-0.25-0.15
Net Cash from Financing Activities16.587.736.27-0.399.8017.871.702.622.43
Summary
Net Change in Cash4.35-3.51-1.80-9.991.0814.72-1.05-1.111.78
Cash at Beginning of Period1.194.716.5016.5015.420.691.742.851.07
Cash at End of Period5.541.194.716.5016.5015.420.691.742.85
Free Cash Flow-11.39-11.25-8.07-9.61-8.72-3.14-2.75-3.73-1.68
Supplemental Disclosures
Interest Paid-0.00-------

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Processa Pharmaceuticals Cash Flow

What is Processa Pharmaceuticals's free cash flow?

Processa Pharmaceuticals had negative free cash flow of $11.39M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$11.39M minus $5.00 of capital expenditures.

How much does Processa Pharmaceuticals spend on capital expenditures?

Processa Pharmaceuticals spent $5.00 on capital expenditures in fiscal 2025, compared with $3.24K a year earlier.

Does Processa Pharmaceuticals pay dividends or buy back shares?

Yes. In fiscal 2025 Processa Pharmaceuticals returned $10.40K in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition